Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.

Pacmilimab demonstrated anti-tumor effects in MC38 tumor model mice that matched the effects of the parental antibody at the same dose. [1]
Pacmilimab predominantly clustered in tumor tissues of PD-L1-expressing mice, with minimal uptake in peripheral non-tumorigenic lymphoid tissues. This distributional property suggests that its uptake in non-tumorigenic PD-L1-expressing tissues is limited and may contribute to the maintenance of immune self-tolerance. [1]

Human

Monoclonal

Unconjugated